2023
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
Speers C, Symmans W, Barlow W, Trevarton A, The S, Du L, Rae J, Shak S, Baehner R, Sharma P, Pusztai L, Hortobagyi G, Hayes D, Albain K, Godwin A, Thompson A. Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. Journal Of Clinical Oncology 2023, 41: 1841-1848. PMID: 36649570, PMCID: PMC10082279, DOI: 10.1200/jco.22.01499.Peer-Reviewed Original ResearchConceptsBreast Recurrence ScoreAnthracycline-based chemotherapyDisease-free survivalRecurrence scoreEndocrine therapyTherapy indexAdjuvant anthracycline-based chemotherapyNode-positive breast cancerAdjuvant endocrine therapyPrimary end pointSubset of patientsPostmenopausal patientsChemotherapy benefitTreatment armsPrognostic indexPrognostic informationBreast cancerPrognostic assessmentPrognostic performancePatientsEnd pointTumor samplesChemotherapyClinical validationProportional hazards assumption
2015
Predictive and Prognostic Value of the TauProtein in Breast Cancer.
Bonneau C, Gurard-Levin ZA, Andre F, Pusztai L, Rouzier R. Predictive and Prognostic Value of the TauProtein in Breast Cancer. Anticancer Research 2015, 35: 5179-84. PMID: 26408675.Peer-Reviewed Original ResearchConceptsBreast cancerTau protein expressionTau proteinPrognostic valueTau expressionHuman epidermal growth factor receptor 2 (HER2) expressionEpidermal growth factor receptor 2 expressionLow tau expressionProtein expressionSubset of patientsReceptor 2 expressionIncreased response rateEffects of taxanesNodal statusBetter prognosisPredictive markerTaxane resistanceChemotherapy sensitivityPredictive valueResponse ratePubMed databaseDrug resistanceCancerHormone receptorsTaxanesPD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunology Research 2015, 3: 326-332. PMID: 25527356, PMCID: PMC4390454, DOI: 10.1158/2326-6066.cir-14-0133.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesPD-L1 expressionPathologic complete responseNeoadjuvant chemotherapyPD-L1Breast cancerDeath 1 ligand 1PD-L1 protein expressionYale-New Haven HospitalHigh PD-L1Antitumor immune activitySubset of patientsTriple-negative patientsBreast cancer patientsTriple-negative statusImmune checkpoint proteinsImmune regulatory moleculesNew Haven HospitalSignificant multivariate modelRabbit monoclonal antibodyTILs correlateComplete responseImmune therapyCancer patientsImmune activity
2011
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?
Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, Pusztai L. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Annals Of Oncology 2011, 22: 2387-2393. PMID: 21406473, DOI: 10.1093/annonc/mdq786.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerBreast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Baseline risk estimatesBN0M0 breast cancerHER2-positive cohortNode-negative T1aStudy end pointDisease-free survivalRisks of therapyGrowth factor receptor 2Subset of patientsPositive breast cancerRetrospective database analysisHER2-negative cancersRecent retrospective studiesHER2-positive cancersFactor receptor 2Small cohort sizeAdjuvant therapyAdjuvant trastuzumabComorbid illnessesCardiac eventsAbsolute benefit
2009
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer
Caudle A, Gonzalez-Angulo A, Kelly H, Liu P, Pusztai L, Symmans W, Kuerer H, Mittendorf E, Hortobagyi G, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2009, 27: 603-603. DOI: 10.1200/jco.2009.27.15_suppl.603.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyHigh Ki-67High tumor gradeStable diseasePR statusBreast cancerTumor gradeKi-67Negative ERNegative ER/PR statusFirst-line surgical approachSingle comprehensive cancer centerTumor progressionER/PR statusTaxane-based regimensComplete pathologic responseSubset of patientsLymph node metastasisHigher T stageComprehensive cancer centerPre-treatment characteristicsNCT regimenLymphovascular invasionMost patientsPathologic response
2007
Markers predicting clinical benefit in breast cancer from microtubule-targeting agents
Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Annals Of Oncology 2007, 18: xii15-xii20. PMID: 18083698, DOI: 10.1093/annonc/mdm534.Peer-Reviewed Original ResearchConceptsMicrotubule-targeting agentsSubset of patientsEstrogen receptor negativityBreast cancer patientsNon-cross resistanceMicrotubule-associated protein tauMechanism of actionReceptor negativityClinical benefitPatient groupCancer patientsClinical trialsPoor responseHER2 amplificationClinical dataClinical studiesBreast cancerTaxane resistanceBetaIII-tubulinProtein tauP-glycoproteinPharmacogenomic analysisTaxanesLow expressionPatientsEstrogen receptor expression and efficacy of docetaxel in early breast cancer: A pooled analysis of 3,490 patients included in two randomized trials
Andre F, Broglio K, Roche H, Martin M, Penault-Lorca F, Hortobagyi G, Berry D, Pusztai L. Estrogen receptor expression and efficacy of docetaxel in early breast cancer: A pooled analysis of 3,490 patients included in two randomized trials. Journal Of Clinical Oncology 2007, 25: 537-537. DOI: 10.1200/jco.2007.25.18_suppl.537.Peer-Reviewed Original ResearchEfficacy of docetaxelRisk of deathER-positive diseaseER-negative diseaseEstrogen receptor expressionER expressionER statusPooled analysisAdjuvant chemotherapyHazard ratioRandomized trialsReceptor expressionBreast cancerAxillary node-positive breast cancerNode-positive breast cancerDocetaxel-containing regimenEarly breast cancerSubset of patientsPositive breast cancerAdjuvant treatment trialsSignificant risk reductionAdjuvant settingClinical characteristicsDocetaxel therapyOverall survivalInclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
Mazouni C, Kau S, Frye D, Andre F, Kuerer H, Buchholz T, Symmans W, Anderson K, Hess K, Gonzalez-Angulo A, Hortobagyi G, Buzdar A, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Annals Of Oncology 2007, 18: 874-880. PMID: 17293601, DOI: 10.1093/annonc/mdm008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsBridged-Ring CompoundsChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Administration ScheduleFemaleFluorouracilHumansMiddle AgedNeoplasms, Hormone-DependentPaclitaxelPrognosisReceptors, EstrogenSurvival AnalysisTaxoidsTumor BurdenConceptsPathologic complete response rateComplete response rateER-negative tumorsPreoperative chemotherapyPCR rateER statusBreast cancerResponse rateEstrogen receptor-positive breast cancerReceptor-positive breast cancerMD Anderson Cancer CenterBreast cancer benefitER-negative statusInclusion of taxanesER-negative patientsER-positive patientsER-positive tumorsNeo-adjuvant therapyType of regimenClinical tumor sizeSubset of patientsCox regression analysisER-negative cancersPositive breast cancerAnderson Cancer Center
2005
Adjuvant therapy for breast cancer.
Hennessy B, Pusztai L. Adjuvant therapy for breast cancer. Minerva Obstetrics And Gynecology 2005, 57: 305-26. PMID: 16166938.Peer-Reviewed Original ResearchConceptsBreast cancerAromatase inhibitorsAdjuvant chemotherapyAdjuvant therapyHormonal therapyHormone receptor-positive breast cancerLymph node-positive breast cancerHormone receptor-positive cancersNode-positive breast cancerReceptor-positive breast cancerAdjuvant chemotherapy regimensAnthracycline-based regimenChemo-therapeutic treatmentsIncorporation of trastuzumabSingle best treatmentAdjuvant hormonal therapyOverall survival advantageUse of trastuzumabDose of cyclophosphamideLarge randomized studiesSchedule of administrationSubset of patientsReceptor-positive cancersRisk of relapseImportant clinical advance
2004
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma
Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL, Drake RR, Vlahou A. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 2004, 100: 1814-1822. PMID: 15112261, DOI: 10.1002/cncr.20203.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsy, NeedleBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Administration ScheduleFemaleFluorouracilHumansMastectomyMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelPostoperative CarePreoperative CareProteomicsRisk AssessmentSensitivity and SpecificitySurvival AnalysisTreatment OutcomeConceptsBreast carcinomaHealthy womenPreoperative chemotherapyFinal tumor responseSubset of patientsDay 3 posttreatmentAdjuvant chemotherapyPostoperative chemotherapyCyclophosphamide chemotherapyFAC chemotherapyMicrometastatic diseasePaclitaxel chemotherapyNormal womenTumor responsePlasma profilesHealthy volunteersChemotherapyPatientsStage ICarcinomaDay 0Single courseWomenPlasma samplesCandidate markers